Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ACLX
stocks logo

ACLX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
15.29M
+0.14%
-1.059
+21.69%
6.49M
-20.14%
-1.146
+1.39%
6.54M
-13.4%
-1.220
+29.79%
Estimates Revision
The market is revising Downward the revenue expectations for Arcellx, Inc. (ACLX) for FY2025, with the revenue forecasts being adjusted by -32.98% over the past three months. During the same period, the stock price has changed by -5.74%.
Revenue Estimates for FY2025
Revise Downward
down Image
-32.98%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+1.66%
In Past 3 Month
Stock Price
Go Down
down Image
-5.74%
In Past 3 Month
Wall Street analysts forecast ACLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACLX is 114.71 USD with a low forecast of 88.00 USD and a high forecast of 134.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Analyst Rating
Wall Street analysts forecast ACLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACLX is 114.71 USD with a low forecast of 88.00 USD and a high forecast of 134.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Buy
2 Hold
0 Sell
Strong Buy
Current: 68.450
sliders
Low
88.00
Averages
114.71
High
134.00
Current: 68.450
sliders
Low
88.00
Averages
114.71
High
134.00
Citi
Buy
maintain
$110
2025-11-24
Reason
Citi
Price Target
$110
2025-11-24
maintain
Buy
Reason
Citi believes today's weakness in Arcellx is "an overreaction to the highly preliminary" Phase 1 inMMyCAR data for Kelonia Therapeutics' KLN-1010. While the achievement of MRD-negativity is a positive early signal, the study featured just three patients and a maximum of three months' follow-up, "leaving critical questions about response durability entirely unanswered," according to the firm, which would be buyers on the weakness. Citi maintains a Buy rating and $110 price target on Arcellx shares.
Wolfe Research
Peer Perform
initiated
2025-11-17
Reason
Wolfe Research
Price Target
2025-11-17
initiated
Peer Perform
Reason
Wolfe Research initiated coverage of Arcellx with a Peer Perform rating and no price target. The firm's analyst of the FDA's FAERS data suggests Carvytki's neurotoxicity is decreasing, but the analyst says its "early to draw any conclusions."
Canaccord
John Newman
Buy
maintain
$121 -> $130
2025-11-03
Reason
Canaccord
John Newman
Price Target
$121 -> $130
2025-11-03
maintain
Buy
Reason
Canaccord analyst John Newman raised the firm's price target on Arcellx to $130 from $121 and keeps a Buy rating on the shares. The firm conducted a detailed analysis of factors limiting Legend / JnJ's CARVYKTI CART launchin Multiple Myeloma, which all suggest favorable launch conditions for Arcellx in 2026. They said based on their analysis of US CARVYKTI revenues, the first four quarters of the CARVYKTI revenue could have been about 2x higher, accounting for issues with Out Of Specification (OOS) product, slow manufacturing time, and infrastructure limitations.
Stifel
Stephen Willey
resume
$129
2025-10-16
Reason
Stifel
Stephen Willey
Price Target
$129
2025-10-16
resume
Reason
Stifel analyst Stephen Willey resumed coverage of Arcellx with a Buy rating and $129 price target. The firm believes anito-cel is "poised to emerge" as a best-in-class BCMA-targeting CAR T therapy for multiple myeloma and anticipates a year-end 2025 BLA submission of iMMagine-1 data to serve as the basis of an approval and launch in the second half of 2026. From there, it expects early-FY27 iMMagine-3 mPFS data serving as the basis of label expansion into second-line and later patients, the analyst tells investors.
Citi
initiated
$110
2025-06-18
Reason
Citi
Price Target
$110
2025-06-18
initiated
Reason
Scotiabank
Outperform -> NULL
downgrade
$133 -> $93
2025-05-09
Reason
Scotiabank
Price Target
$133 -> $93
2025-05-09
downgrade
Outperform -> NULL
Reason
Scotiabank lowered the firm's price target on Arcellx to $93 from $133 and keeps an Outperform rating on the shares. While iMMagine-1 results support an ultimately positive trial outcome in end-stage multiple myeloma, changes at Centers for Biologics Evaluation and Research warn of new regulatory risk that has begun and will continue to weigh on the anito-cel regulatory path, the analyst tells investors.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Arcellx Inc (ACLX.O) is -15.27, compared to its 5-year average forward P/E of -20.91. For a more detailed relative valuation and DCF analysis to assess Arcellx Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-20.91
Current PE
-15.27
Overvalued PE
-7.35
Undervalued PE
-34.47

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-18.42
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-7.64
Undervalued EV/EBITDA
-29.21

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
42.68
Current PS
0.00
Overvalued PS
94.03
Undervalued PS
-8.67
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

ACLX News & Events

Events Timeline

(ET)
2025-11-24
14:04:17
Guggenheim: Concerns Over Arcellx's Competitive Position Are Exaggerated
select
2025-08-07 (ET)
2025-08-07
16:06:50
Arcellx reports Q2 EPS (94c), consensus ($1.03)
select
2025-05-14 (ET)
2025-05-14
09:34:13
Arcellx announces data from iMMagine-1 study of anitocabtagene autoleucel
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-25SeekingAlpha
Arcellx Plummets After Kelonia CAR-T Therapy Results for Multiple Myeloma Are Released

  • Arcellx Stock Reaction: Arcellx (ACLX) shares fell approximately 17% following the release of early-stage results from Kelonia Therapeutics' CAR-T therapy for multiple myeloma, which showed promising early responses in a small trial.

  • Kelonia's CAR-T Therapy: Kelonia's KLN-1010 demonstrated minimal residual disease negativity in all three trial participants at one month, with CAR-T cell expansion observed without the need for lymphodepleting chemotherapy or apheresis, although the follow-up period was only three months.

  • Analyst Perspectives: Analysts from Guggenheim and Citi maintained buy ratings on Arcellx, suggesting that the perceived threat from Kelonia's therapy is overstated due to the small trial size and lack of long-term safety data.

  • Upcoming Presentations: Both Arcellx and Kelonia are set to present their findings on anito-cel and KLN-1010 at the American Society of Hematology 2025 Annual Meeting in December.

[object Object]
Preview
8.0
11-24NASDAQ.COM
Options Trading for Arcellx (ACLX) in the First Week of January 2026

  • Put Contract Overview: The $90.00 put contract has a bid of $5.30, allowing investors to buy ACLX shares at an effective cost of $84.70, which is a 2% discount from the current price of $92.01. There is a 59% chance the contract may expire worthless, potentially yielding a 5.89% return on cash commitment.

  • Call Contract Overview: The $115.00 call contract has a bid of $0.40, and if shares are purchased at $92.01 and the call is sold, it could yield a total return of 25.42% if exercised by January 2026. There is an 81% chance this contract may also expire worthless, providing a 0.43% additional return.

  • Volatility Insights: The implied volatility for the put contract is 61%, while the call contract has an implied volatility of 59%. The actual trailing twelve-month volatility is calculated at 50%.

  • YieldBoost Concept: The term "YieldBoost" is used to describe the potential returns from both the put and call contracts, highlighting the additional income investors can earn through these options strategies.

[object Object]
Preview
4.0
10-16Benzinga
Stifel Reaffirms Buy Rating for Arcellx with $129 Price Target

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.

  • Exclusive Community: Joining Benzinga Pro connects traders with over 10,000 members, providing access to exclusive stories and insights from Benzinga reporters.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Arcellx Inc (ACLX) stock price today?

The current price of ACLX is 68.45 USD — it has decreased -6.16 % in the last trading day.

arrow icon

What is Arcellx Inc (ACLX)'s business?

Arcellx Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering immunotherapies for patients with cancer and other incurable diseases. Its lead program is a BCMA-targeting ddCAR product candidate called anitocabtagene autoleucel, which is being evaluated in its pivotal Phase II iMMagine-1 and the Phase III iMMagine-3 trials in patients with relapsed or refractory multiple myeloma (rrMM). Anitocabtagene is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes its novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. It is also developing two clinical-stage ARC-SparX programs in Phase I trials: ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

arrow icon

What is the price predicton of ACLX Stock?

Wall Street analysts forecast ACLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACLX is 114.71 USD with a low forecast of 88.00 USD and a high forecast of 134.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Arcellx Inc (ACLX)'s revenue for the last quarter?

Arcellx Inc revenue for the last quarter amounts to 4.95M USD, decreased -80.99 % YoY.

arrow icon

What is Arcellx Inc (ACLX)'s earnings per share (EPS) for the last quarter?

Arcellx Inc. EPS for the last quarter amounts to -0.99 USD, increased 106.25 % YoY.

arrow icon

What changes have occurred in the market's expectations for Arcellx Inc (ACLX)'s fundamentals?

The market is revising Downward the revenue expectations for Arcellx, Inc. (ACLX) for FY2025, with the revenue forecasts being adjusted by -32.98% over the past three months. During the same period, the stock price has changed by -5.74%.
arrow icon

How many employees does Arcellx Inc (ACLX). have?

Arcellx Inc (ACLX) has 163 emplpoyees as of December 05 2025.

arrow icon

What is Arcellx Inc (ACLX) market cap?

Today ACLX has the market capitalization of 3.96B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free